About RaCRx Bio
Strong science. Disciplined development. Real impact.
RaCRx Bio is a biotherapeutics company that advances promising oncology and metabolic disease programs from the lab to patients through disciplined, capital-efficient development.
Our Mission
Bringing new treatment options to patients who need them.
To bring new treatment options to children and adults living with cancer, metabolic diseases, and rare conditions by advancing strong science into novel therapies through discipline, partnership, and a focus on patient impact.
How We Work
From discovery to patients, efficiently.
We develop oncology and metabolic disease therapeutics with discipline. Each program starts with a Target Product Profile — a clear definition of the product we intend to deliver. A staged, milestone-driven plan is then constructed using that profile.
01Program Evaluation
We identify therapeutic programs that show strong scientific promise but need a clear development path. We focus on programs where a well-defined product profile offers a credible, efficient path forward — including in rare and childhood diseases.
02Disciplined Development
Each program advances through preclinical work, regulatory planning, and early proof-of-concept clinical studies. We work with focused specialists, academic investigators, and industry partners who join each program when their expertise matters most.
03Capital-Efficient Partnering
We pair non-dilutive funding opportunities — government research grants and foundation support — with strategic private investment. Collaboration structures are built around defined work, shared milestones, and aligned incentives, not large upfront costs.
Where We Focus
Four areas. One disciplined approach.
Oncology
Therapeutic programs designed for clearly defined patient populations with unmet needs. We pursue programs grounded in strong biology and credible early data.
Metabolic Diseases
Novel approaches to metabolic conditions, developed with a clear view of the intended patient and clinical benefit. When the science supports it, we chart a path to broader patient populations.
Rare Diseases
Programs for well-defined patient groups where focused development and specialized regulatory pathways — including Orphan Drug and RMAT designations — can accelerate the path to patients.
Childhood Diseases
We actively pursue programs for pediatric populations, where unmet need is high and focused development with the right partners can make a meaningful difference.
Regulatory Strategy
Deep expertise in FDA, EMA, and PMDA engagements, accelerated approval pathways, IND preparation, and NDA/BLA filings that reduce risk and shorten development timelines.
Unaddressed Opportunities
Promising science that has been overlooked, under-resourced, or set aside — and that can be advanced with the right focus, partners, and capital strategy.
Our Portfolio
A growing portfolio of focused programs.
RaCRx Bio manages a growing portfolio of oncology and metabolic disease programs at different stages of development, from preclinical work to clinical studies. Each program advances as a focused effort with its own development plan, team of specialists, and funding strategy. Shared leadership, governance, and operating expertise come from the parent company.
RaCRx Enhance
Therapeutics, diagnostics, and enabling technologies advancing oncology and metabolic disease programs.
RaCRx Fusion
AI-driven computational biology and data integration accelerating drug discovery and precision medicine.
RaCRx Flight
Opportunity scouting, venture building, and strategic evaluation identifying the next generation of programs.
Ready to explore a partnership?
We welcome conversations with academic institutions, biotech companies, clinical investigators, and investors aligned with patient-focused, capital-efficient development in oncology and metabolic diseases.
Get in Touch